FDA and the pharmaceutical industry appear to have a shared interest in finding ways to dramatically increase expanded access programs to avoid a potentially difficult fight over 'Right to Try' legislation at the federal level in 2017. A September 22 hearing on a pending Senate bill illustrates why.
Who is to blame when terminally ill patients are unable to gain access to an experimental therapy that they believe offers the only hope for treating their condition?
A Sept. 22 hearing in the Senate Homeland Security & Government Affairs Committee largely focused on FDA as...